Osimertinib Monograph for Professionals - Drugs.com
ウェブ2023年9月27日 · Osimertinib (Monograph) Brand name: Tagrisso Drug class: Antineoplastic Agents Medically reviewed by Drugs.com on Sep 27, 2023. Written by ASHP. Introduction Uses Dosage Warnings Interactions Stability FAQ Introduction
Osimertinib Uses, Side Effects & Warnings - Drugs.com
ウェブWhat is osimertinib? Osimertinib is used to treat non-small cell lung cancer that is positive for an abnormal "EGFR" gene. You doctor will test you for this gene. Osimertinib is sometimes given when the cancer has spread to other parts of the body (metastatic), or may come back after surgery.
Osimertinib: Uses, Interactions, Mechanism of Action ...
ウェブOsimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. 1, 9 Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by …
Tagrisso: Uses, Dosage, Side Effects & Warnings - Drugs.com
ウェブLast updated on Feb 22, 2024. Uses. Warnings. Before taking. Dosage. Side effects. Interactions. FAQ. What is Tagrisso? Tagrisso (osimertinib) is an oral (taken by mouth) kinase inhibitor that may be used to treat adults with non-small cell lung cancer (NSCLC) whose tumors have certain abnormal epidermal growth factor receptor (EGFR) gene (s).
Osimertinib - Wikipedia
ウェブOsimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
Osimertinib in Untreated - The New England Journal of Medicine
ウェブ2017年11月18日 · Osimertinib is an oral, third-generation, irreversible EGFR-TKI that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M resistance mutations, with lower activity against wild-type...
Overall Survival with Osimertinib in Untreated, EGFR-Mutated ...
ウェブ2019年11月21日 · Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M...
Treating disease progression with osimertinib in EGFR ...
ウェブ2021年10月9日 · Osimertinib, a third-generation, wild-type sparing, irreversible EGFR tyrosine kinase inhibitor (TKI), originally showed a striking activity after progression to first- and second-generation EGFR-TKIs when T790M resistance mutation was identified.
Osimertinib: Dosage, Mechanism/Onset of Action, Half-Life ...
ウェブ2020年2月10日 · Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which binds to select mutant forms of EGFR, including T790M, L858R, and exon 19 deletion at lower concentrations than wild-type.
Osimertinib with or without Chemotherapy in EGFR-Mutated ...
ウェブ2023年11月8日 · Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) that potently and selectively inhibits both EGFR-TKI–sensitizing and...
コンテンツに移動